

MUNICIPAL YEAR 2014/2015 - REPORT NO.

MEETING TITLE AND DATE
Health and Wellbeing Board
14 April 2015

Director of Public Health

Contact officer and telephone number:
Allison Duggal, Consultant in Public
Health T: 020 83792894
E mail:
allison.duggal@enfield.gov.uk

Agenda - Part: 1	Item: 4
Subject: Enfield Pharmaceutical Needs Assessment 2015	
Wards: All	
Cabinet Member consulted:	
Approved by:	

1. EXECUTIVE SUMMARY

A Pharmaceutical Needs Assessment (PNA) is the way in which HWBs, local Authorities, The NHS and other public sector partners work together to understand the current and future pharmaceutical needs of the local population. The Health and Wellbeing Board (HWB) has a statutory duty to produce a PNA every 3 years and there is currently a requirement for a PNA to be published by April 2015.

This paper outlines the steps taken to ensure that the PNA produced for Enfield is fit for purpose, including a 60 day consultation period. The PNA has been considered by the PNA Steering Group and found to be ready for publication

Failure to produce a robust PNA can lead to legal challenges because of the PNA's relevance to decisions about commissioning services and the opening of additional, new pharmacies.

2. RECOMMENDATIONS

It is recommended that the health and wellbeing board:

- Agrees to the publication of the new Pharmaceutical Needs Assessment attached as appendix 1 of this report.
- Takes into consideration the statutory requirement to meet its obligation to publish the PNA by April 2015.

3. BACKGROUND

3.1 The NHS (Pharmaceutical and local Pharmaceutical Services) Regulations 2013 require Health and Wellbeing boards (HWB)s to produce a Pharmaceutical Needs Assessment (PNA), identifying any changes and producing updated maps and Statements for their respective areas. A steering group, sponsored by the Director of Public health, and chaired by a Consultant in Public Health was set up to oversee the production of the PNA. This was a multiagency group consisting of key local stakeholders. The group reported to the HWB on a quarterly basis. Any decisions that were made outside the steering group meeting were ratified by the group at the next meeting hence there is full accountability from the steering group.

3.2 A revised assessment of the pharmaceutical needs was necessary in order to prevent significant detriment to the provision of pharmaceutical services in Enfield because of the significant changes in the population since 2011, particularly with respect to the underestimation in total population revealed by the census (1.6%;n=5044).

3.3 The steering group ensured that the statutory guidelines were followed and process was inclusive to all stakeholders and all sections of the community. The minimum requirements of the good PNA are outlined in Regulation 4 and schedule 1 of the 2013 Regulations. The matters to which each HWB must have regard in preparing its PNA are outlined in Regulation 9. Consultation on the draft PNA took place between 1 December 2014 and 31 January 2015, meeting the 60 day consultation requirement. The consultation process is outlined in *Appendix G, Stakeholder Engagement*, of the PNA document. Responses to the consultation are attached as *Appendix H* and these were incorporated in the final draft of the PNA. An equalities impact assessment was undertaken and will be published with the PNA.

3.4 The PNA will be reviewed after three years. Arrangements to keep the maps up-to-date and update any changes which are likely to impact on pharmaceutical services through supplementary statements are being negotiated. Any supplementary statements will be logged with NHS England and published alongside the PNA document on the council's website.

4. ALTERNATIVE OPTIONS CONSIDERED

4.1 There were no alternative options considered because of the information detailed in para 3.2, which eliminated the option of a review of the existing PNA of 2011 produced by the PCT.

5. REASONS FOR RECOMMENDATIONS

5.1 Enfield HWB has a duty to publish a fit for purpose PNA by April 2015. The Steering group which was appointed to oversee the production of the PNA is giving assurance that the process met the statutory guidelines, it was fair and inclusive.

6. COMMENTS OF THE DIRECTOR OF FINANCE, RESOURCES AND CUSTOMER SERVICES AND OTHER DEPARTMENTS

6.1 Financial Implications

The Pharmaceutical Needs Assessment was produced by an external consultant and the work on it has now been completed. Payment has been made in 14/15 to the consultant for around £25k (with a further £5k incurred for the costs of running the PNA consultation). This was a scheduled piece of work within the Public Health area in 14/15 which is now complete and pending publication given the approval of the Health & Wellbeing Board

6.2 Legal Implications

Pursuant to the NHS (Pharmaceutical and local Pharmaceutical Services) Regulations 2013 require Health and Wellbeing boards (HWB)s to publish a Pharmaceutical Needs Assessment (PNA). Failure to do so would be a breach of the Council's statutory duty.

A representative from Legal Services was on the PNA Steering Group. The PNA is in a form approved by Legal Services.

7. KEY RISKS

Failure to produce a robust PNA can lead to legal challenges because of the PNA's relevance to decisions about commissioning services and the opening of additional, new pharmacies. This can have an adverse impact on the Council's reputation.

8. IMPACT ON PRIORITIES OF THE HEALTH AND WELLBEING STRATEGY

8.1 Ensuring the best start in life

The PNA will guide commissioners to ensure that pharmaceutical services are easily accessible and provide the necessary service to promote health and dispense medicine to support and improve antenatal and perinatal health and provisions for 0-5year requirements, which will improve the chances of the best start in life for families in Enfield.

8.2 Enabling people to be safe, independent and well and delivering high quality health and care services

The PNA shows the opening hours for all pharmacies and the pharmacies that are commissioned to deliver additional specialist health services like sexual health, methadone management, electronic dispensing and others.

This enables the local residents to be safe and independent knowing that they have a pharmacy within walking distance, knowing the pharmacy is able to meet their specific health needs and allows commissioners to be sure that the services are well distributed across the borough to ensure that local needs are proportionately catered for across the borough. This constitutes a high quality care service.

8.3 Creating stronger, healthier communities

The PNA will facilitate accurate and up to date information to commissioners which will enable fit for purpose commissioning and opening the market to the right providers. This means that Enfield residents will have access to the right level of pharmaceutical services resulting in stronger, healthier communities.

8.4 Reducing health inequalities – narrowing the gap in life expectancy

Rigorous consultation took place during the process of developing the PNA. Local residents and all major groups and organisations with vested interest in health service provision in Enfield were invited to be part of the steering group or consulted throughout the process. Responses were incorporated in the PNA document. Pharmaceutical service mapping was aligned with some of the key major health pressure points to ensure those areas had the relevant and adequate service levels. Future developments were taken into consideration to ensure that the pharmaceutical needs cater for the potential population growth in particular areas will be catered for.

8.5 Promoting healthy lifestyles

Having the right numbers of pharmacies which are within walking distance as well as commissioning pharmacies to provide specific services in targeted areas will improve healthy lifestyles.

9. EQUALITIES IMPACT IMPLICATIONS

An Equalities impact Assessment was conducted and the PNA considers the protected characteristics under the Equalities Act 2010.

Background Papers

None